Trivant Custom Portfolio Group’s Organogenesis Holdings ORGO Stock Holding History

Trivant Custom Portfolio Group’s Portfolio ORGO Stock Details ORGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5,452	Closed	-$23.6K	–	172
2025 Q1	$23.6K	Hold	5,452	–	–	0.01%	122
2024 Q4	$17.4K	Hold	5,452	–	–	0.01%	123
2024 Q3	$15.6K	Hold	5,452	–	–	0.01%	125
2024 Q2	$15.3K	Buy	5,452 +1,702	+45%	+$4.57K	0.01%	142
2024 Q1	$10.7K	Hold	3,750	–	–	0.01%	156
2023 Q4	$15.3K	Hold	3,750	–	–	0.01%	156
2023 Q3	$11.9K	Sell	3,750 -10,843	-74%	-$34.5K	0.01%	153
2023 Q2	$48.4K	Hold	14,593	–	–	0.03%	109
2023 Q1	$31.1K	Buy	+14,593	New	+$36.1K	0.02%	141

Other funds holding ORGO

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Trivant Custom Portfolio Group's ORGO Position: Q2 2025 in Review

Trivant Custom Portfolio Group sold out of Organogenesis Holdings (ORGO) in Q2 2025, closing a stake of 5,452 shares — an estimated $23.6K sold.

Trivant Custom Portfolio Group first reported a position in ORGO in Q1 2023 and held it in 9 quarters. The position peaked at $48.4K in Q2 2023. 115 funds tracked by Wall St. Rank hold ORGO as of Q2 2025.

Trivant Custom Portfolio Group reported no remaining Organogenesis Holdings position as of Q2 2025 after selling out during the quarter.
Trivant Custom Portfolio Group sold 5,452 Organogenesis Holdings shares in Q2 2025, an estimated $23.6K.
Trivant Custom Portfolio Group first reported a position in Organogenesis Holdings in Q1 2023 and held it in 9 quarters.
Trivant Custom Portfolio Group's Organogenesis Holdings position peaked at $48.4K in Q2 2023.
115 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q2 2025.

Based on Trivant Custom Portfolio Group's 13F filing for Q2 2025, filed 12 Aug 2025.